Moderna gets further $472 million U.S. award for coronavirus vaccine development




  • In Business
  • 2020-07-26 15:01:01Z
  • By Reuters
Moderna Therapeutics seen during COVID-19 in Massachusetts
Moderna Therapeutics seen during COVID-19 in Massachusetts  

(Reuters) - Moderna Inc said on Sunday it has received an additional $472 million from the U.S. government's Biomedical Advanced Research and Development Authority (BARDA) to support development of its novel coronavirus vaccine.

The U.S.-based drug maker said the additional funding will support its late-stage clinical development including the expanded Phase 3 study of Moderna's vaccine candidate.

In April, Moderna had received $483 million from the U.S. federal agency that funds disease-fighting technology, when the experimental vaccine was in an early-stage trial conducted by the U.S. National Institutes of Health.

"Encouraged by the Phase 1 data, we believe that our mRNA vaccine may aid in addressing the COVID-19 pandemic and preventing future outbreaks," Chief Executive Officer Stéphane Bancel said in a press release.

BARDA's total funding for the experimental vaccine of Moderna, the first in the United States to begin human trials of a coronavirus vaccine, is now about $955 million.

The vaccine uses synthetic messenger RNA (mRNA) to inoculate against the coronavirus. Such treatments help the body immunize against a virus and can potentially be developed and manufactured more quickly than traditional vaccines.

A Phase 3 study, conducted in collaboration with the National Institute of Allergy and Infectious Diseases, will begin on July 27 and involve about 30,000 participants, according to the company.

Moderna said it remains on track to be able to deliver about 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021.

The announcement about further funding came two days after the drug developer said its formula used in developing the vaccine was not covered under patents owned by Arbutus Biopharma

Pfizer Inc, Novavax Inc, Britian's AstraZeneca Plc are other few drug makers that received funding from BARDA for coronavirus vaccine development.


(Reporting by Maria Ponnezhath in Bengaluru; Editing by Will Dunham)

COMMENTS

More Related News

Biggest coronavirus vaccine deal yet: $2.1 billion to Sanofi/GSK for up to 100 million doses
Biggest coronavirus vaccine deal yet: $2.1 billion to Sanofi/GSK for up to 100 million doses

The United States will pay Sanofi and GlaxoSmithKline up to $2.1 billion to test and produce 100 million doses of an experimental coronavirus vaccine.

White House coronavirus testing czar says it
White House coronavirus testing czar says it's time to 'move on' from hydroxychloroquine

"The evidence just doesn't show that hydroxychloroquine is effective, for now," Brett P. Giroir said despite the drug being touted by President Trump.

U.S. CDC reports 4,542,579 coronavirus cases
U.S. CDC reports 4,542,579 coronavirus cases
  • US
  • 2020-08-01 17:59:19Z

The CDC reported its tally of cases of COVID-19, an illness caused by the new coronavirus, as of 4 p.m. ET on July 31, versus its previous report a day earlier. The CDC figures do not necessarily reflect cases reported by individual states.

Coronavirus updates: Fauci confident vaccine will get to Americans in 2021; Southwest bans BYOB; MLB continues to struggle
Coronavirus updates: Fauci confident vaccine will get to Americans in 2021; Southwest bans BYOB; MLB continues to struggle

Dr. Fauci remains confident that a vaccine will be ready by early next year. Southwest is fed up with passengers bringing their own alcohol. More news.

Bill Gates is quietly advocating for the US to lead the global fight against COVID-19
Bill Gates is quietly advocating for the US to lead the global fight against COVID-19

The U.S. hasn't led the global fight against the coronavirus pandemic. A Senate bill would devote $3 billion for vaccines in the poorest countries.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business